Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

The Double-edged Sword of Diabetes Drug Development

Dec 01 2005

• By Mark Ratner

Related Content

Shadow FDA? Researchers Are Taking Approval Matters into their Own Hands

Dec 01 2005

In-licensing Drugs for Personalized Medicine: What You Know, When You Know It

Jul 01 2005

Will Late Loss Debate Stifle Device Start-Up Innovation?

Nov 01 2005

Related Companies

Bristol Myers Squibb Company

Merck & Co., Inc.

AstraZeneca PLC

Takeda Pharmaceutical Co. Ltd.

Nektar Therapeutics

Pfizer Inc.

Sanofi

OSI Systems, Inc.

Genentech, Inc.

Sangamo Therapeutics, Inc.

CymaBay Therapeutics, Inc.

Merck & Co., Inc.

Perlegen Sciences, Inc.

Mitsubishi Tanabe Pharma Corporation

Phenomix Corporation

Roche Holding AG

Takeda Pharmaceutical Co. Ltd.

Plexxikon, Inc.

Wyeth

Alba Therapeutics Corporation

DiaKine Therapeutics, Inc.

Additional Topics

Regulation BioPharmaceutical

More from Archive

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window